Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, Potent And Selective IRAK4 Degrader, In Adult Healthy Volunteers And HS Patients

Loading news article.

Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, Potent And Selective IRAK4 Degrader, In Adult Healthy Volunteers And HS Patients | WAPE

Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, Potent And Selective IRAK4 Degrader, In Adult Healthy Volunteers And HS Patients

Article summary

Related companies

Comments —